Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Landgren

Showing results (341-350 of 519) with videos related to

Pageof 52
Sort By:
Leukemia & Lymphoma|October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiencyAdebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
BMC Medical Genetics|November 17, 2010
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Ke Zhang, et al.
Haematologica|February 4, 2017
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patientsMonika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2019
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaAdam R Bryant, Patrick Hilden, Sergio Giralt, et al.
American Journal of Hematology|August 19, 2014
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposiumOla Landgren, Nicole Gormley, Danielle Turley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple MyelomaEric Smith, Sean M Devlin, Satyajit Kosuri, et al.
Blood Advances|January 4, 2018
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based studyMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Molecular Oncology|January 17, 2014
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasmsJohn K Simmons, Jyoti Patel, Aleksandra Michalowski, et al.
British Journal of Haematology|March 22, 2016
Monoclonal gammopathy-associated pure red cell aplasiaNeha Korde, Yong Zhang, Kelsey Loeliger, et al.
Leukemia & Lymphoma|May 31, 2017
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myelomaMatthew J Pianko, Samuel A Funt, David B Page, et al.
Pageof 52

Showing results (341-350 of 519) with videos related to

Sort By:
Pageof 52
Leukemia & Lymphoma|October 14, 2016
Upfront use of plerixafor and granulocyte-colony stimulating factor (GCSF) for stem cell mobilization in patients with multiple myeloma: efficacy and analysis of risk factors associated with poor stem cell collection efficiencyAdebayo Ogunniyi, Mabel Rodriguez, Sean Devlin, et al.
BMC Medical Genetics|November 17, 2010
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndromeWanlong Ma, Hagop Kantarjian, Ke Zhang, et al.
Haematologica|February 4, 2017
A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patientsMonika Engelhardt, Anne-Saskia Domm, Sandra Maria Dold, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 8, 2019
Presalvage International Staging System Stage and Other Important Outcome Associations in CD34<sup>+</sup>-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple MyelomaAdam R Bryant, Patrick Hilden, Sergio Giralt, et al.
American Journal of Hematology|August 19, 2014
Flow cytometry detection of minimal residual disease in multiple myeloma: Lessons learned at FDA-NCI roundtable symposiumOla Landgren, Nicole Gormley, Danielle Turley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 2, 2015
CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple MyelomaEric Smith, Sean M Devlin, Satyajit Kosuri, et al.
Blood Advances|January 4, 2018
Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based studyMarianna Thordardottir, Ebba K Lindqvist, Sigrun H Lund, et al.
Molecular Oncology|January 17, 2014
TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasmsJohn K Simmons, Jyoti Patel, Aleksandra Michalowski, et al.
British Journal of Haematology|March 22, 2016
Monoclonal gammopathy-associated pure red cell aplasiaNeha Korde, Yong Zhang, Kelsey Loeliger, et al.
Leukemia & Lymphoma|May 31, 2017
Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myelomaMatthew J Pianko, Samuel A Funt, David B Page, et al.
Pageof 52